3. D’Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic
indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31:468-75.
4. Llach J, Ginés P, Arroyo V, Rimola A, Tito L, Badalamenti S, Jimenez W,
Gaya J, Rivera F, Rodes J. Prognostic value of arterial pressure, endogenous
vasoactive systems and renal function in cirrhotic patients admitted to the
hospital for the treatment of ascites. Gastroenterology 1988; 94:482-7.
5. Salerno F, Borroni G, Moser P, Badalamenti S, Cassara L, Maggi A, Fusini
M, Cesana B. Survival and prognostic factors of cirrhotic patients with ascites:
a study of 134 outpatients. Am J Gastroenterol 1993; 88:514-9.
6. Bernardi M, Caraceni P, Trevisani F, Sica G, Colantoni A, Gasbarrini A.
Impact of ascites on survival of patients with liver cirrhosis. In: Surrogate
Markers in Liver Disease, Puopon R, Reichen J, Ed; Kluwer Academic Publishers:
Dordrecht 1996; 88-101.
7. Barrowman JA, Granger DN. Effects of experimental cirrhosis on splanchnic
microvascular fluid and solute exchange in the rat. Gastroenterology 1984;
87:165-72. 8. Wood LJ, Colman J, Dudley FJ. The relationship between portal
pressure and plasma albumin in the development of cirrhotic ascites. J Gastroenterol
Hepatol 1987; 2:525-31.
9. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral
arterial vasodilation hypothesis: a proposal for the initiation of renal sodium
and water retention in cirrhosis. Hepatology 1988; 8:1151-58
10. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later:
pathophysiology and clinical consequences. Hepatology 1994; 20:1359-63.
11. Møller S, Henriksen JH. The systemic circulation in cirrhosis. In: Ascites
and renal dysfunction in liver disease, Arroyo V, Ginès P, Rodés J, Schrier
RW, eds. Malden MA: Blackwell Science Inc, 1999; 307-29.
12. Bernardi M, Caraceni P. Pathogenesis of ascites and hepatorenal syndrome:
altered haemodynamics and neurohumoral systems. In: Gerbes AL, Beuers U, Jüngst
D, Pape GR, Sackmann M, Sauerbruch T, Eds. Hepatology 2000. Dordrecht: Kluwer
Academic Publishers 2001; 185-203.
13. MacGilchrist AJ, Summer D, Reid JL. Impaired pressor reactivity in cirrhosis:
evidence for a peripheral vascular defect. Hepatology 1991; 13:689-94.
14. Bernardi M, Rubboli A, Trevisani F, Cancellieri C, Ligabue A, Baraldini
M, Gasbarrini G.. Reduced cardiovascular responsiveness to exercise-induced
sympatho-adrenergic stimulation in patients with cirrhosis. J Hepatol 1991;
12:207-16.
15. Ryan J, Sudhir K, Jennings G, et al. Impaired reactivity of the peripheral
vasculature to pressor agents in alcoholic cirrhosis. Gastroenterology 1993;
105:1167-72.
16. Islam MZ, Williams BC, Madhavan KK, et al. Selective alteration of agonist-mediated
contraction in hepatic arteries isolated from patients with cirrhosis. Gastroenterology
2000; 118: 765-71.
17. Martin PY, Schrier RW. Nitric oxide and systemic and renal hemodynamic
disturbances in cirrhosis. In: Ascites and renal dysfunction in liver disease:
pathogenesis, diagnosis and treatment, Arroyo V, Ginès P, Rodés J, Schrier
RW, eds. Malden MA: Blackwell Science Inc 1999; 273-90.
18. Oberti F, Sogni P, Cailmail S, Moreau R, Pipy B, Lebrec D. Role of prostacyclin
in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic
portal hypertension. Hepatology 1993; 18:621-7.
19. Ginés P, Fernandez-Esparrach G, Arroyo V, Rodés J. Pathogenesis of ascites
in cirrhosis. Semin Liver Dis 1997; 17:175-89.
20. Bernardi M, Trevisani F, Caraceni P. The renin-angiotensin-aldosterone
system in cirrhosis. In: “The Liver and the Kidney”, Schrier RW, Arroyo V,
Rodés J, Ginés O, Blackwell Scientific Pub: Malden MA 1999; 175-97.
21. Ginès P, Berl T, Bernardi M, Bichet D, Hamon G, Jiménez W, Liard J, Martin
P, Schrier RW. Hyponatremia in cirrhosis: from pathogenesis to treatment.
Hepatology 1998; 28:851-864.
22. Runyon BA. Management of adult patients with ascites caused by cirrhosis.
Hepatology 1998; 27:264-72.
25. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen
NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure:
effect of posture. Br Med J 1986; 292: 1351-53.
26. Arroyo V, Ginès P, Saló J. A European survey on the treatment of ascites
in cirrhosis. J Hepatol 1994; 21:667-72.
27. Descos L, Gauthier A, Levy VG, Michel H, Quinton A, Rueff B, Fermanian
J, Fombonne E, Durbec JP. Comparison of six treatments of ascites in patients
with liver cirrhosis. A clinical trial. Hepatogastroenterology 1983; 30:15-20.
28. Strauss E, De Sa MF, Lacet CM, Cartapattida da Silva E, Dos Santos RW.
Padronizaçao de conduta terapeutica das ascites do hepatopata cronico. Estudo
prospectivo de 100 casos. Gastroenterol Endosc Dig 1985; 4:79-86.
29. Gauthier A, Levy VG, Quinton A, Michel H, Rueff B, Descos L, Durbec JP,
Fermanian J, Lancrenon S. Salt or no salt in the treatment of cirrhotic ascites:
a randomised study. Gut 1986; 27: 705-9.
30. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S, Marra F, Trevisani
F, Gasbarrini G, Naccarato R, Gentilini P. Efficacy and safety of the stepped
care medical treatment of ascites in liver cirrhosis: a randomized controlled
clinical trial comparing two diets with different sodium content. Liver 1993;
13:156-62.
31. Reynolds TB, Lieberman FL, Goldman AR. Advantages of treatment of ascites
without sodium restriction and without complete removal of excess fluid. Gut
1978;19:549-53.
32. Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis
in the ascitic patient: a randomized controlled trial of three regimens. J
Clin Gastroenterol 1981; 3 (Suppl 1): 73-80.
33. Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F,
Rodés J. Randomized comparative study of efficacy of furosemide versus spironolactone
in patients with liver cirrhosis and ascites. Gastroenterology 1983; 84:961-68.
34. Karim A. Spironolactone metabolism in man revisited. In: Brunner HR Ed,
Contemporary Trends in Diuretic Therapy. Amsterdam: Excerpta Medica 1986;
22-37. 35. Bernardi M, Servadei D, Trevisani F, Servadei D, Gasbarrini G.
Importance of plasma aldosterone concentration on the natriuretic effect of
spironolactone in patients with liver cirrhosis and ascites. Digestion 1985,
31:189-93.
36. Andriulli A, Arrigoni A, Gindro T, Karbowiak I, Buzzetti G, Armanini D.
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients
during long-term K-canrenoate or spironolactone therapy. Digestion 1989; 44:155-62.
37. Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis
in cirrhosis. Ann Intern Med 1979; 90:338-40.
38. Lant A. Diuretics. Clinical pharmacology and therapeutic use (Part II).
Drugs 1985; 29:162-88.
39. Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, Ceolotto
G, Gatta A. Randomized clinical study of the efficacy of amiloride and potassium
canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;
19:72-9. 40. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites
from chronic liver disease: the importance of peripheral edema. Gastroenterology
1986; 90:1827-33. 41. Bernardi M, De Palma R, Trevisani F, Santini C, Patrono
D, Motta R, Servadei D, Gasbarrini G. Effects of a new loop diuretic (muzolimine)
in cirrhosis with ascites: comparison with furosemide. Hepatology 1986; 6:400-5.
42. Laffi G, Marra F, Buzzelli G, Azzena G, Meacci E, De Feo ML, La Villa
G, Gentilini P. Comparison of the effects of torasemide and furosemide in
nonazotemic cirrhotic patients with ascites: a randomized, double-blind study.
Hepatology 1991; 13:1101-05.
43. Ginés P, Arroyo V, Quintero E, Planas R, Bory F, Cabrera J, Rimola A,
Viver J, Camps J, Jiménez W, et al. Comparison of paracentesis and diuretics
in the treatment of cirrhotics with tense ascites. Results of a randomized
study. Gastroenterology 1987; 93:234-41.
44. Tito L, Gines P, Arroyo V, Planas R, Panes J, Rimola A, Llach J, Humbert
P, Badalamenti S, Jimenez W, Rodes J. Total paracentesis associated with intravenous
albumin management of patients with cirrhosis and ascites. Gastroenterology
1990; 98:146-51.
45. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized
comparative study of hemaccel vs. albumin infusion after total paracentesis
in cirrhotic patients with refractory ascites. Hepatology 1991; 13:707-13.
46. Planas R, Gines P, Arroyo V, Llach J, Panes J, Vargas V, Salmeron JM,
Gines A, Toledo C, Rimola A, Jimenez W, Asbert M, Gassul MA, Rodes J. Dextran-70
versus albumin as plasma expanders in cirrhotic patients with tense ascites
treated with total paracentesis. Results of a randomized study. Gastroenterology
1990; 99:1736-1744. 47. Conn HO. The paracentesis pendulum. Hepatology 1985;
5:521-22.
48. Cabrera J, Inglada L, Quintero E, Jimenez W, Losada A, Mayor J, Guerra
C. Large-volume paracentesis and intravenous saline: effects on the reninangiotensin
system. Hepatology 1991; 14:1025-28.
49. Ginés A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis
R, Angeli P, Ruiz-Del Arbol L, Planas R, Sola R, Ginés P, Terg R, Inglada
L, Vaque P, Salerno F, Vargas V, Clemente G, Quer JC, Jiménez W, Arroyo V,
Rodés J. Randomised trial comparing albumin, dextran 70, and polygeline in
cirrhotic patients with ascites treated by paracentesis. Gastroenterology
1996; 111:1002-10.
50. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P,
Planas R, Lebrec D, Geuvel A, Elewaut A, Adler M, Arroyo V. Diuretic requirements
after therapeutic paracentesis in non-azotemic patients with cirrhosis. A
randomized double-blind trial of spironolactone versus placebo. J Hepatol
1997; 26:614-20.
51. Arroyo V, Ginès P, Gerbes A, Dudley FJ, Gentilini P, Laffi G, Reynolds
TB, Ring-Larsen H, Scholmerich J. Definition and diagnostic criteria of refractory
ascites and hepatorenal syndrome. Hepatology 1996; 23:164-76.
52. Blendis LM, Greig PD, Langer B, Baigrie RS, Ruse J, Taylor BR. The renal
and hemodynamic effects of the peritoneovenous shunt for intractable hepatic
ascites. Gastroenterology 1979; 77: 250-7.
53. Stanley MM, Ochi S, Lee KK, , Nemchausky BA, Greenlee HB, Allen JI, Allen
MJ, Baum RA, Gadacz TR, Camara DS. Peritoneovenous shunting as compared with
medical treatment in patients with alcoholic cirrhosis and massive ascites.
Veterans Administration Cooperative Study on Treatment of Alcoholic Cirrhosis
with Ascites. N Engl J Med. 1989; 321:1632-8.
54. Gines P, Arroyo V, Vargas V, Planas R, Casafont F, Panes J, Hoyos M, Viladomiu
L, Rimola A, Morillas R, Salmeron JM, Gines A, Esteban F, Rodes J. Paracentesis
with intravenous infusion of albumin as compared with peritoneovenous shun-ting
in cirrhosis with refractory ascites. N Engl J Med. 1991; 325:829-35.
55. Gines A, Planas R, Angeli P, Guarner C, Salerno F, Gines P, Salo J, Rodriguez
N, Domenech E, Soriano G, Rodes J. Treatment of patients with cirrhosis and
refractory ascites using LeVeen shunt with titanium tip: comparison with therapeutic
paracentesis. Hepatology. 1995; 22:124-31. 56. Jalan R, Lui HF, Redhead DN,
Hayes PC. TIPSS 10 years on. Gut 2000; 46:578-81.
57. Wong F, Sniderman K, Liu P, Allidina Y, Sherman M, Blendis L. Transjugular
intrahepatic portosystemic stent shunt: effects on hemodynamics and sodium
homeostasis in cirrhosis and refractory ascites. Ann Intern Med 1995; 122:816-22.
58. Quiroga J, Sangro B, Nunez M, Bilbao I, Longo J, Garcia-Villarreal L,
Zozaya JM, Betes M, Herrero JI, Prieto J. Transjugular intrahepatic portal-systemic
shunt in the treatment of refractory ascites: effect on clinical, renal, humoral,and
hemodynamic parameters. Hepatology 1995; 21:986-94.
59. Somberg KA, Lake JR, Tomlanovich SJ, LaBerge JM, Feldstein V, Bass NM.
Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment
of clinical and hormonal response and renal function. Hepatology 1995; 21:709-16.
60. Ochs A, Rossle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker
M, Langer M, Blum HE. The transjugular intrahepatic portosystemic stent-shunt
procedure for refractory ascites. N Engl J Med 1995; 333:878-9.
61. Lebrec D, Giuily N, Hadengue A, Vilgrain V, Moreau R, Poynard T, Gadano
A, Lassen C, Benhamou JP, Erlinger S. Transjugular intrahepatic portosystemic
shunts: comparison with paracentesis in patients with cirrhosis and refractory
ascites: a randomized trial. French Group of Clinicians and a Group of Biologists.
J Hepatol 1996; 25:135-144.
62. Rossle M, Ochs A, Gulberg V, Siegerstetter V, Holl J, Deibert P, Olschewshi
M, Reiser M, Gerbes AL. A comparison of paracentesis and transjugular intrahepatic
portosystemic shunting in patients with ascites. New Engl J Med 2000; 342:1701-1707.
63. Wong F, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis
after transjugular intrahepatic portosystemic shunt. Gastroenterology 1997;
112:899-907.
64. Deschenes M, Dufresne MP, Bui B, Fenyves D, Spahr L, Roy L, Lafortune
M, Pomier-Layrargues G. Predictors of clinical response to transjugular intrahepatic
portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
Am J Gastroenterol 1999; 94:1361-5.
65. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model
to predict poor survival in patients undergoing transjugular intrahepatic
portosystemic shunts. Hepatology 2000; 31:864-71.
66. Chalasani N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD.
Determinants of mortality in patients with advanced cirrhosis after transjugular
intrahepatic portosystemic shunting. Gastroenterology 2000; 118:138-44.
67. Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann
Intern Med 1997;126: 57-62.
68. Adam R, Cailliez V, Majno P, Karam V, McMaster P, Caine RY, O’Grady J,
Pichlmayr R, Neuhaus P, Otte JB, Hoeckerstedt K, Bismuth H. Normalised intrinsic
mortality risk in liver transplantation: European Liver Transplant Registry
study. Lancet 2000; 356:621-7.
69. Haagsma EB, Gips CH, Wesenhagen H, Van Imhoff GW, Krom RA. Liver disease
and its effect on haemostasis during liver transplantation. Liver 1985; 5:123-28.
70. Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, Van Thiel DH. Prognostic
value of preoperatively obtained clinical and laboratory data in predicting
survival following orthotopic liver transplantation. Hepatology 1986; 6:922-7.
71. Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH.
Effects of renal impairment on liver transplantation. Gastroenterology 1987;
93:148-56.
72. Rimola A, Navasa M, Grande L. Liver transplantation in cirrhotic patients
with ascites. In: Ascites and renal dysfunction in liver disease, Arroyo V,
Ginès P, Rodés J, Schrier RW, eds. Malden MA: Blackwell Science Inc, 1999;
522-37.
73. Roberts MS, Pinson CW, Karlson C, Stone M, Rohrer R, Jenkins RL. Predictors
of intraoperative death and long-term survival in liver transplantation. A
multistage analysis. Transplant Proc 1989; 21:2439-42.
74. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS.
Impact of pretransplant renal function on survival after liver transplantation.
Transplantation 1995; 59:361-5.
75. Gonzalez E, Rimola A,Navasa M, Andreu H, Grande L,Garcia-Valdecasas JC,
Cirera I,Visa J, Rodes J. Liver transplantation in patients with non-biliary
cirrhosis: prognostic value of preoperative factors. J Hepatol 1998; 28:320-8.